Krsnaa Diagnostics growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+7.8%+15.7%+27.2%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+11.4%+31.8%+17.9%
+19.3%+46.1%+1.7%
+30.7%+36.5%−8.5%
+30.2%+34.3%−9.5%
+42.3%+9.4%+28.8%
+11.1%+9.0%+9.6%
+63.9%+258.7%−68.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

KRSNAA₹497.95

Krsnaa Diagnostics Limited

· Pharma & Health
₹ CrorePeersSURAKSHAHEALTHXNEPHROPLUS3BBLACKBIOMcap ₹1,615 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+27.2+15.7+7.8—
EBITDA Growth—+17.9+31.8+11.4—
EBIT Growth—+1.7+46.1+19.3—
Net Income Growth—-8.5+36.5+30.7—
EPS Growth—-9.5+34.3+30.2—
Total Assets Growth—+28.8+9.4+42.3—
Total Equity Growth—+9.6+9.0+11.1—
Cash from Operations Growth—-68.1+258.7+63.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.